Helping deliver a patient-centric future in oral solid dosage manufacturing

January 23, 2026

Remove from favorites

Add to favorites

The Pfizer CentreOne eBook explores the evolving landscape of oral solid dosage (OSD) drug development and manufacturing and highlights how the industry can adapt to meet rising demand for efficient, high‑quality OSD products. It explains why OSD forms remain the most widely used mode of drug delivery worldwide, thanks to patient convenience, stable shelf life, flexible dosing options, and cost‑effectiveness. For manufacturers and formulators, the guide outlines several key trends shaping the future of OSD production, including the adoption of Pharma 5.0 technologies such as automation, artificial intelligence (AI), machine learning (ML), real‑time monitoring, digital twins, and process analytical technology (PAT) to improve efficiency, quality, and speed.

The eBook also discusses how patient expectations are influencing formulation design — from modified‑release and fixed‑dose combinations to mini‑tablets, multiparticulates, and other personalized oral formats — and the manufacturing challenges they present, such as achieving uniformity and process control. Another major theme is the increased use of challenging APIs, including poorly soluble and highly potent compounds, which require specialized handling, containment, regulatory compliance, and advanced processing techniques. To navigate this complexity and deliver OSD products reliably, the guide positions Pfizer CentreOne’s global capabilities and expertise as a strategic partner with broad technological and regulatory experience, supporting formulation, scale‑up, technology transfer, and commercial manufacturing.